Beijing Strong Biotechnologies Inc Class A

Beijing Strong Biotechnologies Inc Class A

SSZSE:300406
12.79
CNY
0.00
(0.00%)
0.43EPS
27.85P/E
7.00BMarket Cap
Mar 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.11
2.44
2.26
1.35
1.4
1.54
1.67
1.59
2.72
2.6
2.99
2.87
2.28
2.35
Basic EPS, GAAP
0.45
1.01
0.98
0.55
0.55
0.6
0.66
0.21
0.69
0.67
0.9
0.93
0.32
0.43
Free Cash Flow per Basic Share
0.34
0.72
0.36
0.34
0.37
0.37
0.25
0.2
0.47
0.52
0.75
0.94
0.89
- -
Dividend per Share
0.24
- -
0.25
0.15
0.3
0.15
0.15
0.15
0.13
0.16
0.11
0.21
0.91
0.35
Book Value per Share
1.19
1.98
2.35
2.78
3.05
3.39
3.93
5.43
4.88
5.56
6.33
7.01
6.46
6.15
Tangible Book Value per Share
1.18
1.98
2.35
2.77
2.48
2.82
3.35
2.47
1.92
2.6
3.38
4.07
3.81
3.52
Basic Weighted Avg Shares
399
209
250
494
497
501
502
535
588
581
582
579
593
585
Sales/Revenue/Turnover
445
508
566
667
694
774
841
848
1,599
1,511
1,742
1,659
1,356
1,374
Operating Margin (%)
46.99
46.98
49.9
45.58
46.47
44.78
45.88
23.02
36.1
35.26
37.28
39.79
35.03
39.92
Depreciation Expense
11
11
11
12
17
16
21
30
44
55
56
71
72
- -
Net Income, GAAP
181
211
245
272
273
301
332
112
406
389
524
538
190
251
Effective Tax Rate (%)
14.64
14.46
14.52
14.04
14.88
14.08
13.16
11.14
12.54
12.22
12.04
13.51
19.35
19.82
Profit Margin (%)
40.63
41.44
43.28
40.7
39.34
38.84
39.44
13.24
25.36
25.75
30.07
32.45
14.01
18.24
Working Capital
396
919
1,055
1,215
1,110
1,119
904
1,528
1,133
1,769
2,037
2,303
2,028
1,982
LT Debt
- -
- -
- -
- -
71
6
- -
264
767
1,018
1,132
1,129
1,068
1,091
Total Equity
476
987
1,175
1,388
1,530
1,702
1,971
3,423
2,913
3,269
3,722
4,119
3,783
3,601
Return on Invested Capital (%)
40.26
27.94
22.38
20.95
18.15
17.49
17.3
4.77
12.27
9.68
11.53
10.82
3.84
5.01
Return on Capital (%)
41.71
28.79
22.12
20.33
18.01
17.67
17.36
3.81
9.29
10.23
12.28
11.45
4.51
5.85
Return on Common Equity (%)
41.91
28.79
22.67
21.2
18.72
18.6
18.06
4.34
13.36
12.66
14.97
13.72
4.8
6.52

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
14
2
8
LT Borrowings
1,072
1,080
1,086
LT Finance Leases
4
4
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
586
586
586
Market Capitalization
6,936
6,408
6,999

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,349
2,109
2,191
Cash, Cash Equivalents & STI
673
505
588
Accounts Receivable, Net
1,050
1,027
1,020
Inventories
189
193
183
Total Current Liabilities
193
178
209
Payables & Accruals
- -
- -
- -
ST Debt
14
2
8
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.28%
2.73%
-8.16%
Free Cash Flow
28.51%
47.29%
-3.75%
Net Income, GAAP
19.55%
45.97%
-64.73%
Sales/Revenue/Turnover
11.82%
15.06%
-18.29%
Total Cash Common Dividend
48.72%
81.32%
332.51%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
394
428
416
422
1,659
2025
320
349
- -
344
1,356
2026
335
344
351
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.21
0.22
0.21
0.27
0.93
2025
0.14
0.16
- -
-0.14
0.32
2026
0.18
0.18
0.21
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.21
2025
- -
0.42
- -
0.2
0.91
2026
- -
- -
0.15
- -
- -

Company Description

CEO
Yong Li Wang
Full Time Employees
998
Sector
Health technology
Industry
Medical specialties
Address
Kuang Yi Building Beijing BE China 100191
IPO Date
Oct 21, 2014
Business
Beijing Strong Biotechnologies, Inc. (300406.SZ) researches, develops, manufactures, and sells in-vitro diagnostics (IVD) products and services primarily in China and internationally. Founded in 2001 and headquartered in Beijing, China, the company offers a comprehensive portfolio of clinical biochemistry reagents covering liver, renal, lipid, cardiac, diabetes, special protein, tumor marker, pancreas, inorganic, inflammation, therapeutic drug monitoring (TDM), and other panels using enzymatic, immunoturbidimetric, latex immunoturbidimetric, CEDIA, and EMIT methods; coagulation reagents including routine and special items under the Beijing MDC brand; blood grouping cards and systems utilizing DG Gel card technology launched in 2018; and instruments such as automated coagulation analyzers, automatic biochemistry analyzers, automated blood grouping analyzers, and fully automatic chemiluminescence immunoassay analyzers. It operates through brands GCELL for biochemistry and blood typing, and Beijing MDC for coagulation, serving hospitals, pharmaceuticals, and institutions with a nationwide sales network in China and global marketing channels, while maintaining strategic partnerships with Abbott, Roche, Hitachi, Mindray, and Weigao. Recent developments include the acquisition of Beijing MDC in 2017 to expand its coagulation testing product line, the purchase of 65.55% of Maixin Biotech in 2020 with a potential full acquisition of remaining shares announced in 2021 to enhance tumor pathology diagnostics, multiple new reagent approvals such as N-terminal pro-brain natriuretic peptide kits and digoxin assay kits from Beijing regulators in 2024-2025, six biochemistry kits gaining TÜV Rheinland IVDR certification, and completion of a shareholding increase by China National Pharmaceutical Investment totaling 4.34 million shares in December 2024.